Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?

Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?

What are the consequences and benefits of adding patient organisations to existing alliances? How do these collaborations work? How do they create value for the whole life sciences community? What is the actual influence on patients of public/private partnerships? What is the actual involvement of patient organisation in financing the collaborations?

Elli Karagianni

SNE/ Scientific Project Officer – Patient engagement
Belgium
IMI – Innovative Medicines Initiative

Andreas L.G. Reimann

Managing Partner, Co-Founder
Germany
admedicum Business for Patients

Olivier Arnaud

Senior Director
France
JDRF – Juvenile Diabetes Research Foundation

Mathias Schmidt

CEO
USA
ArmaGen

Mathieu Jouannin

Global Alliance Manager – Public Private Partnerships, Sanofi
France
Sanofi
Scroll to Top
  • No products in the cart.